logo-loader
viewhVIVO PLC

hVIVO merger with Open Orphan 'gives it the chance to achieve profitability'

hVIVO PLC's (LON:HVO) Dr Trevor Phillips caught up with Proactive London's Andrew Scott following the news they're to merge with Open Orphan PLC (LON:ORPH).

Open Orphan intends to maintain the existing research and development activities of hVIVO, relative to supporting hVIVO's clinical developments services offering.

Phillips says the deal will allow hVIVO shareholders to be part of a larger business with greater growth potential.

Quick facts: hVIVO PLC

Price: 16.5 GBX

LSE:HVO
Market: LSE
Market Cap: £13.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of hVIVO PLC named herein, including the promotion by the Company of hVIVO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: DeepMatter to collaborate with AstraZeneca

Headlines from the Proactive UK newsroom. DeepMatter (LON:DMTR) has agreed a tie-up with AstraZeneca to combine their drug development technology platforms. Deepmatter uses AI to monitor and record chemical reactions during drug development. Rare disease database group Open Orphan...

on 9/12/19

2 min read